Component
Rat oral shikimic-acid exposure
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Nominal oral shikimic acid produced Cmax 904 ng/mL and estimated bioavailability 10.4% in rats.
Experimental context and source evidence
- evidence_access
- Primary full text retrieved; relevant methods/results/figures reviewed. Selective extraction, not raw-data reanalysis or exhaustive supplemental extraction.
- experimental_model
- Male Sprague–Dawley rats, five per route; nominal oral 100 mg/kg versus intravenous 2 mg/kg.
- interpretation_status
- Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
- limitations
- Species/route-specific pharmacokinetic estimate, not human exposure. Rat nominal-dose arithmetic caveat and complete time parameters remain in the source passage.
- plain_language
- Nominal oral shikimic acid produced Cmax 904 ng/mL and estimated bioavailability 10.4% in rats.
- primary_references
- Pharmacokinetics of Shikimic Acid Following Intragastric and Intravenous Administrations in Rats. | 2020 | DOI 10.3390/pharmaceutics12090824 | PMID 32872397 | https://pubmed.ncbi.nlm.nih.gov/32872397/ | https://doi.org/10.3390/pharmaceutics12090824 | https://pmc.ncbi.nlm.nih.gov/articles/PMC7558350/
- source_locator
- Reviewed reference lines 47-47; exact primary location described in quoted passage where extracted.
Shikimic acid: detailed mechanisms of action (reviewed 5 October 2026) · lines 47–47
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Male Sprague–Dawley rats, five per route; nominal oral 100 mg/kg versus intravenous 2 mg/kg. · source_derived_draft · unverified_draft
**Rat exposure is measurable but incomplete.** In five male Sprague–Dawley rats per route, reported oral shikimic acid 100 mg/kg produced Cmax 904 ± 48 ng/mL (calculated 5.19 µM), Tmax 2.7 ± 1.5 h and terminal half-life 1.26 ± 0.20 h. The intravenous comparator was 2 mg/kg; estimated absolute bioavailability was 10.4%. The Methods contains a dose/volume arithmetic inconsistency, so these are the nominal dose and Table 3 estimates, not an independently reconstructed administered dose. Occasional double peaks do not prove enterohepatic recycling. Neither rat transport mechanism nor human oral exposure is established by these numbers. [Pharmacokinetics of Shikimic Acid Following Intragastric and Intravenous Administrations in Rats.](https://pubmed.ncbi.nlm.nih.gov/32872397/)
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.